SARS-CoV-2 mAbs Continued to Be Used After FDA Deauthorization

TUESDAY, Aug. 30, 2022 -- More than 158,000 doses of two anti-severe acute respiratory syndrome coronavirus 2 monoclonal antibodies (mAbs), bamlanivimab-etesevimab and casirivimab-imdevimab, were administered in early 2022, despite deauthorization...